ADARx Pharmaceuticals, Inc.
ADRXHealthcare|Biotechnology|US
$13.23
-0.06 (-0.45%)
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07428499 Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) | Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1 | P3 | Recruiting | 90 | Double-blind | ADX-324 Dose Level 1, ADX-324 Dose Level 2 |
| NCT06960213 STOP-HAE: A Phase 3 Study of ADX-324 in HAE | Hereditary Angioedema, HAE | P3 | Recruiting | 90 | RCT, Double-blind | ADX-324, Placebo |
| NCT05876312 Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients | Paroxysmal Nocturnal Hemoglobinuria (PNH) | P1P2 | Recruiting | 50 | RCT, Double-blind | ADX-038, Placebo |
| NCT05691361 Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients | Hereditary Angioedema | P1P2 | Active | 53 | RCT, Double-blind | ADX-324, Placebo |
| NCT07522099 Chinese Adults With Kidney Disease | Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G) | P2 | Recruiting | 30 | Open-label | ADX-038, Telitacicept |
| NCT06990269 Phase 2 Study of ADX-038 in Participants With Geographic Atrophy | Geographic Atrophy Secondary to Age-related Macular Degeneration | P2 | Recruiting | 240 | RCT, Double-blind | ADX-038, Placebo |
| NCT06989359 Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease | IgAN, C3G | P2 | Recruiting | 45 | Open-label | ADX-038 Dose Level 2, ADX-038 Dose Level 1 |
| NCT06205628 Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension | Hypertension, Hypertension,Essential | P1 | Active | 28 | RCT, Double-blind | ADX-850, Placebo |
| NCT07081503 Phase 1 Study of ADX-626 in Healthy Participants | Healthy Adult Participants | P1 | Recruiting | 44 | RCT, Double-blind | ADX-626, Placebo |